










New discovery holds potential as tuberculosis drug
By Lauren Roberts
Brian VanderVen, assistant professor of
microbiology and immunology, and colleagues at
Cornell’s College of Veterinary Medicine, have
discovered a key metabolic mechanism in
Mycobacterium tuberculosis(Mtb) bacteria, which
presents as a novel drug target for potentially
treating tuberculosis. The �nding is published in
the journal eLife.
Mtb, which currently infects nearly 1.5 billion
people and causes more than 1 million deaths
each year, requires host lipids (cholesterol and
fatty acids) to maintain infection. This is
considered a de�ning characteristic of this
pathogen, and is thought to support the
bacterium’s ability to persist for long periods of
time in hosts during both latent and active
infections.
However, the mechanisms of how Mtb assimilates
the host’s fatty acids has remained a mystery –
until now.
Using a genetic screen, VanderVen and his team identi�ed genes involved in cholesterol
metabolism. This identi�ed the gene lucA, which encodes a protein of unknown function. To
tease out what the protein does, VanderVen’s team created a novel ΔlucA Mtb mutant, which
revealed that the protein encoded by the gene, LucA, is an integral membrane protein, and is
required for fatty acid and cholesterol uptake in Mtb. Further work determined that LucA
interacts with subunits of speci�c proteins in the Mce1 and Mce4 complexes, which import fatty
acids and cholesterol, respectively. Speci�cally, LucA stabilizes the transporters – acting as an
integral linchpin that, if removed, causes Mce1 and Mce4 to fall apart. VanderVen and his
research group plan to investigate two other transporters in Mtb – Mce2 and Mce3 – using this
same approach.
“Our data highlights the complexities and weaknesses of a highly successful intracellular
pathogen,” said VanderVen. The discovery sheds new light on how Mtb metabolizes fatty acids
and cholesterol, and also �rmly establishes that LucA is required for full virulence of Mtb in
vivo, “and is therefore is a novel drug target in Mtb,” said VanderVen.
The next step for VanderVen and his team will be to investigate drugs that inhibit LucA. “This is
ideal, because LucA is a bottleneck and inhibiting this protein with a chemical could disable two
pathways at a time,” said VanderVen. As it happens, “we already have discovered chemicals that






































Lauren Roberts is assistant director of communications at the College of Veterinary Medicine
and editor of Scopes magazine.
